Castro Beiras A, Muñiz J, Juane R
Grupo Gallego de Estudios Cardiovasculares, Asociación de Estudios Biomédicos de Galicia (BIOMEGA), La Coruña.
Rev Esp Cardiol. 1995;48 Suppl 4:72-80.
This paper is the written version of the conference that under the same title was presented in the XXX Congreso Nacional de la Sociedad Española de Cardiología. In the paper, the use of the most recent antihypertensive drugs is advocated as first line therapy. The defence is based in cardiac and non cardiac considerations. Among the former, there are certain advantages of the new drugs in areas as regression of left ventricular hypertrophy and improvement of coronary flow and coronary reserve. Among the non cardiac considerations there are some metabolic factors (non adverse effect on the lipid profile), as well as a positive effect on some endocrine-metabolic cascades like the insulin-resistance syndrome and a very important role in certain special situations as coexistence with other diseases and individual characteristics of the patient (pregnancy or elderly for example).
本文是在西班牙心脏病学会第XXX届全国大会上发表的同名会议的书面版本。该论文主张将最新的抗高血压药物用作一线治疗。这种主张基于心脏和非心脏方面的考虑因素。在心脏方面，新药在左心室肥厚消退、冠状动脉血流和冠状动脉储备改善等方面具有某些优势。在非心脏方面的考虑因素中，有一些代谢因素（对血脂谱无不良影响），以及对胰岛素抵抗综合征等一些内分泌代谢级联反应有积极作用，并且在某些特殊情况（如与其他疾病并存以及患者的个体特征，例如妊娠或老年）中发挥非常重要的作用。
